Synairgen reported interim results to end-June 2022 that reflected a lower R&D spend on COVID-19-related trials and lower expenses overall. With net cash of £18m at the end of the period augmented by the receipt of a £9.1m R&D tax credit in August, our forecast of net cash of £10m at end-2022 is raised to just under £16m. The Group notes that it has a cash runway until at least end-September 2023, which we view as conservative, and with the introduction of 2023E forecasts, we now estimate end-20 ....
29 Sep 2022
Synairgen - Interim results: good cash runaway and going beyond COVID
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - Interim results: good cash runaway and going beyond COVID
Synairgen plc (SNG:LON) | 6.7 0 0.0% | Mkt Cap: 13.6m
- Published:
29 Sep 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
10
Synairgen reported interim results to end-June 2022 that reflected a lower R&D spend on COVID-19-related trials and lower expenses overall. With net cash of £18m at the end of the period augmented by the receipt of a £9.1m R&D tax credit in August, our forecast of net cash of £10m at end-2022 is raised to just under £16m. The Group notes that it has a cash runway until at least end-September 2023, which we view as conservative, and with the introduction of 2023E forecasts, we now estimate end-20 ....